中國抗體製藥有限公司

SinoMab BioScience Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

SinoMab to attend 2024 BIO International Convention

(28 May 2024 – Hong Kong), SinoMab BioScience Limited ("SinoMab" or the **"Company"**, stock code: **3681.HK)**, a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, will be attending the 2024 BIO International Convention from 3 June to 6 June 2024 in San Diego, California, USA.

Established in 1993, BIO International Convention is the world's largest and most comprehensive industry event for biotechnology and is regarded as one of the most significant gatherings in the industry, providing a platform for biotechnology and pharmaceutical companies, investors, academic institutions, and research and development institutions to promote their work and explore cooperation opportunities.

SinoMab warmly invites you to connect with us at the BIO International Convention in 2024. Reach out to us via email (BDTeam@sinomab.com) and meet with our team in person at the BIO International Convention.



About SinoMab BioScience Limited

SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in mainland China.

The Company's flagship product SM03 (Suciraslimab) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. SM03 (Suciraslimab) has completed the Phase III clinical trial for RA in China and is pending NMPA's marketing approval for RA in China.

Our clinical stage key product SM17 is a novel, first-in-class (FIC) antibody targeting IL-25 receptor with the potential for treating atopic dermatitis, asthma and idiopathic pulmonary fibrosis. In Phase I clinical trials (NCT05332834) performed in the US, SM17 showed a good safety profile with no drug-related serious adverse event (SAE) reported, demonstrating superiority over other JAK1 inhibitor in safety and tolerability. Preclinical setting of SM17 confirmed that animals treated with SM17 exhibited a similar, if not better, therapeutics responses than those treated with the FDA approved JAK1 inhibitor. Study results were published on international scientific journal, *Allergy*, in April 2024.

In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs.

For more information about SinoMab, please visit our website at www.sinomab.com.